Retigabine as adjunctive therapy in refractory partial-onset seizures

Phase 3, randomised, double-blind trial of retigabine in intractable epilepsy (IE) (3 arms), sponsored by Bausch Health. Primary endpoints: Change in total partial seizure frequency per 4 weeks from baseline to double-blind period (900 mg/day vs placebo) and Safety and tolerability. Started Sep 2005; status: completed.